Navigation Links
Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
Date:1/9/2008

SEATTLE, Jan. 9 /PRNewswire/ -- Omeros Corporation announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Omeros. Deutsche Bank Securities Inc. will be acting as the sole book-running manager. Pacific Growth Equities, LLC will be acting as the co- lead manager, and Leerink Swan LLC and Needham & Company, LLC will be acting as co-managers. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus may be obtained from Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telephone at (800)-503-4611 or by email: prospectusrequest@list.db.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urol
'/>"/>

Copyright©2008 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2

Related biology technology :

1. Genelex Corporation Defends Consumers Right to Obtain DNA Information:
2. Pharmos Corporation Completes Initial Closing of Private Placement
3. Pharmos Corporation Announces Board and Management Changes
4. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
7. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
10. FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
11. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...e-FirstCall/ -- BlueFire Ethanol Fuels, Inc. (OTC ...ng the world,s transportation fuel paradigm throug...ic wastes, has been ranked number 19 on the Biofu...ioenergy;" the company,s second consecutive year i...Ethanol among the top 20 bioenergy companies for t...
(Date:12/3/2009).../ -- Nikon Corporation, an innovator of advanced o...gned a licensing agreement with Harvard University...ptical Reconstruction Microscopy (STORM) technolog...nufacture STORM enabled microscopy systems and mar...ration President, Mr. Michio Kariya, and Nikon Ins...
(Date:12/3/2009)...FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: ...elopment of compounds for the treatment of cardiov...t it has completed the last patient visit in its P...The FDG-PET trial enrolled 52 patients and was car...ing Massachusetts General Hospital, Mount Sinai Sc...
(Date:12/3/2009)...ire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. ...ase its financial results for the second quarter o...m. EST and will host a conference call and webcast...ame day. ,, Peregrine,s senior management will ...nded October 31, 2009 and will review recent opera...
Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2
...y unveils landmark program to help clients avoid c...n collecting outcomes data, LINCOLN, R.I., July 1... questioning the integrity of outcomes data in cli...rsy has been in the news. The,truth is, no matter ...d,for, mistakes are easy to make and difficult to ...
...TON, N.J., July 15 Pharmasset, Inc.,(Nasdaq: VRU...itive,agreements dated July 14, 2008 with a select...0 shares of its common stock in a "registered,dire...e the shares at a,purchase price of $17.85 per sha...5.9 million to Pharmasset, before deducting placem...
...A, July 15 CryoLife, Inc. (NYSE: CRY ),a biomate...y, announced,today that second quarter 2008 financ... 2008. The Company will hold a teleconference call... 31, 2008, to discuss the,results, followed by a q...erson, president and CEO of CryoLife, Inc., To li...
Other Biology Technology:QualityMetric Announces QM Certified Scoring Program 2Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock 2Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock 3CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2
(Date:12/4/2009)...matical model of heart cells, University of Iowa i...al enzyme, calmodulin kinase II (CaM kinase), disr... The study, which also involved Columbia Universit...S Computational Biology . , "Recently, research...nase II as a critical regulator of the heart,s res...
(Date:12/3/2009)... N.J., Dec. 3 BIO-key In...ader in wireless public safety and finger-based bi... majority of its shareholders at a Special Shareho...ompany,s Law Enforcement Division to Interact911 M... cast in favor and 1.2% were opposed. ,, (Logo:...
(Date:12/3/2009)...learn new information and adapt to changes in our ...emories, appears to lie in the minute junctions wh...udy by NYU Langone Medicine Center researchers. Th...al Nature . , The scientists, led by Wen-Biao ...uroscience at NYU School of Medicine, discovered t...
Breaking Biology News(10 mins):U-Iowa study helps advance heart-related research 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Lifelong memories linked to stable nerve connections 2AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 1AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 2AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 3AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 4NIA Says Health Care Will Cause U S Dollar Collapse 50998 1NIA Says Health Care Will Cause U S Dollar Collapse 50998 2NIA Says Health Care Will Cause U S Dollar Collapse 50998 3Spa Chefs Prepare You for a Healthy Summer 50996 1Spa Chefs Prepare You for a Healthy Summer 50996 2
...niversity Medical Center scientists have developed...ents with early-stage lung cancer will need chemot...xic regimen of drugs. , The test has the potenti...nding chemotherapy for patients who are currently ...Duke,s Institute for Genome Sciences & Policy....
...wing gentle puffs of air onto a mouse,s whiskers a...iscovering that a long-overlooked signaling system... , The work is the latest in a growing body of evi...ytes aren,t simply support cells but are stars of ...he University of Rochester Medical Center who did ...
...ein long thought to provide only mechanical suppor...ling apart turns out to have much wider utility. I...d to also influence wound healing and maintain the... to Johns Hopkins researchers. , The wound-healing...eds light on how the body repairs wounds and may h...
Other Biology News:First-ever genomic test predicts which lung cancer patients need chemotherapy to live 2First-ever genomic test predicts which lung cancer patients need chemotherapy to live 3First-ever genomic test predicts which lung cancer patients need chemotherapy to live 4Flick of whiskers helps tease out brain's 'shadow' signaling system 2Flick of whiskers helps tease out brain's 'shadow' signaling system 3Bedsores and bald hides: Novel roles revealed for a 'scaffolding' protein 2Bedsores and bald hides: Novel roles revealed for a 'scaffolding' protein 3
Nick Translation System from Invitrogen
...ble, easy-to-use and makes identifying your sample...asy to use Labels withstand extreme lab conditio...te stamp Laboratory symbols Affordable-every t...re efficient Banner mode for general labeling ...
cAMP[125I] Direct SPA Screening Biotrak Assay from GE Healthcare, formerly Amersham Biosciences
E. coli Expression System with Gateway Technology from Invitrogen
Biology Products: